基于细胞衰老基因的膀胱癌预后及免疫治疗风险模型的构建和验证.pdfVIP

3842023504 Cancer Res Prev Treat,2023,Vol.50,No.4

··肿瘤防治研究年第卷第期

doi:10.3971/j.issn.1000-8578.2023.22.1214临床研究

··

基于细胞衰老基因的膀胱癌预后及免疫治疗

风险模型的构建和验证

123

张鹏，杨倩，易东风

ConstructionandValidationofARiskModelforPredictingPrognosisand

ImmunotherapyResponseofBladderCancerBasedonCellularSenescence-relatedGenes

ZHANG Peng123

, YANG Qian, YI Dongfeng

1.DepartmentofUrology,GuizhouProvincialPeople’sHospital,Guiyang550002,China;

2.DepartmentofGastroenterology,GuizhouProvincialPeople’sHospital,Guiyang550002,

China;3.DepartmentofUrology,LichuanPeople’sHospital,Lichuan445400,China

CorrespondingAuthor:YIDongfeng,E-mail:*****************

Abstract:Objective To evaluate the prognosis and immunotherapy response of patients with bladder cancer 

Methods Senescence genes were screened from TCGA-

clinical application value of SRS in bladder cancer. 

BLCA, and cellular SRS genes were screened according to LASSO regression. A bladder cancer risk-score 

modelwasconstructedbasedontheSRSgenestoanalyzethesurvivaldifferenceandmodel-fitdegreeof

TCGA-BLCA high- and low-risk groups. Univariable and multivariable Cox regression was used to analyze 

GEO-BLCAdatabasewereverified,andvariationsinimmunotherapyresponseswereanalyzedinIMvigor210

databases.Accordingtotheresultofβ-galchromogenicreactioninbladdercancerandnormalparacancer

Results Eight marker genes were screened, and 

tissues, the existence of cell senescence was determined. 

P0.05). The area under the ROC curve of TCGA-BLCA in 1-, 3-, and 5-year were 0.657, 

validat